Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 5/2002

01-07-2002 | Letter to the Editor

Is the presence of interleukin-2 receptor alpha in the serum of colorectal liver metastases patients derived from hepatic natural killer cells?

Authors: David Vermijlen, Dianzhong Luo, Mogens Kruhøffer, Torben F. Ørntoft, Peter J. K. Koppen, Eddie Wisse

Published in: Cancer Immunology, Immunotherapy | Issue 5/2002

Login to get access
Metadata
Title
Is the presence of interleukin-2 receptor alpha in the serum of colorectal liver metastases patients derived from hepatic natural killer cells?
Authors
David Vermijlen
Dianzhong Luo
Mogens Kruhøffer
Torben F. Ørntoft
Peter J. K. Koppen
Eddie Wisse
Publication date
01-07-2002
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 5/2002
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-002-0289-z

Other articles of this Issue 5/2002

Cancer Immunology, Immunotherapy 5/2002 Go to the issue

Original Article

Interferon-alpha (Intron A) upregulates urokinase-type plasminogen activator receptor gene expression

Review

The role of CD8+ T cells in immune responses to colorectal cancer

Original Article

Treatment with GM-CSF and IL-2 in patients with metastatic colorectal carcinoma induced high serum levels of neopterin and sIL-2R, an indicator of immune suppression

Original Article

Prediction of an HLA-DR-binding peptide derived from Wilms’ tumour 1 protein and demonstration of in vitro immunogenicity of WT1(124–138)-pulsed dendritic cells generated according to an optimised protocol

Original Article

Frequent detection of anti-recoverin cytotoxic T-lymphocyte precursors in peripheral blood of cancer patients by using an HLA-Aff24-recoverin tetramer

Original Article

Induction of Tc2 cells with specificity for prostate-specific antigen from patients with hormone-refractory prostate cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits